Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

• Status: Unknown status
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial agents which can be used in outpatient for the treatment of non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli. This study was conducted to compare the clinical and bacteriological outcomes of patients with non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli who were treated with intravenous (IV) carbapenems followed by oral sitafloxacin or IV ertapenem.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Ertapenem; Fluoroquinolones; Sitafloxacin

Criteria

Inclusion Criteria:

• Age >18 years

• Acute pyelonephritis by definition

• Positive urine culture for Extended Spectrum Beta Lactamase Escherichia coli ≥105 colony forming unit/mL

• Voluntarily consented to be enrolled in the study

Exclusion Criteria:

• Severe sepsis or septic shock

• Mixed organism of urine culture

• Positive blood culture

• Has other source of infection

• Has mechanical abnormality of urinary tract

• Immunocompromised conditions

• Retained Foley's catheter

• Pregnancy or lactation

• Previous urinary tract infections within 4 weeks

• Contraindicated for fluoroquinolones and carbapenems